Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 5 , Pages 303-305, November 2009

An in vivo proton neurospectroscopy study of cerebral oxidative stress in myalgic encephalomyelitis (chronic fatigue syndrome)

  • B.K. Puri

      Affiliations

    • MRI Unit, Imaging Sciences Department, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0HS, England, UK
    • Corresponding Author InformationCorresponding author. Tel: +442083832412; fax: +442083833038.
  • ,
  • M. Agour

      Affiliations

    • Department of Psychiatry, Cambridge, and University of Hertfordshire, UK
  • ,
  • K.D.R. Gunatilake

      Affiliations

    • Brooklands Hospital, Coleshill Road, Marston Green, Birmingham B37 7HL, UK
  • ,
  • K.A.C. Fernando

      Affiliations

    • The Greenfields, Monyhull Hall Road, Kings Norton, Birmingham B30 3QQ, UK
  • ,
  • A.I. Gurusinghe

      Affiliations

    • Hillingdon Hospital, Pield Heath Road, Uxbridge, Middlesex UB8 3NN, UK
  • ,
  • I.H. Treasaden

      Affiliations

    • Three Bridges Medium Secure Unit, West London Mental Health NHS Trust, Uxbridge Road, Middlesex UB1 3EU and Head of Forensic Neurosciences, Lipid Neuroscience Group, Imperial College London, England, UK

published online 11 November 2009.

Abstract 

A particularly important family of antioxidant defence enzymes in the body are the glutathione peroxidases, which remove H2O2 by coupling its reduction to H2O with oxidation of reduced glutathione (GSH) to oxidised glutathione (GSSG). There are suggestions that GSH in the peripheral blood may be reduced in myalgic encephalomyelitis, which is a highly disabling neurological disease of unknown aetiology. Since many of the symptoms relate to cerebral functioning, it would seem probable that peripheral blood GSH findings would be reflected in lower cerebral GSH levels. The aim of this study was to carry out the first direct assessment of cerebral GSH levels in myalgic encephalomyelitis; the hypothesis being tested was that cerebral GSH levels would be reduced in myalgic encephalomyelitis. Cerebral proton neurospectroscopy was carried out at a magnetic field strength of 3T in 26 subjects; spectra were obtained from 20×20×20mm3 voxels using a point-resolved spectroscopy pulse sequence. The mean cerebral GSH level in the myalgic encephalomyelitis patients was 2.703 (SD 2.311) which did not differ significantly from that in age- and gender-matched normal controls who did not have any history of neurological or other major medical disorder (5.191, SD 8.984; NS). Therefore our study does not suggest that GSH is reduced in the brain in myalgic encephalomyelitis. At the present time, based on the results of this study, there is no evidence to support the suggestion that, by taking glutathione supplements, an improvement in the brain-related symptomatology of myalgic encephalomyelitis may occur.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0952-3278(09)00172-0

doi:10.1016/j.plefa.2009.10.002

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 81, Issue 5 , Pages 303-305, November 2009